BMS Bets $8.4bn On Biokin’s Bispecific ADC

New Validation Of Chinese Innovation

 
• By Dexter Jie Yan

In a record licensing deal involving a single biopharma asset from China, Biokin and its US subsidiary SystImmune will receive up to $8.4bn from BMS, including $800m upfront, for a bispecific ADC with broad oncology potential. 

acquisition deal
BL-B01D1 adds another ADC to BMS's diverse pipeline • Source: Shutterstock

More from China

More from Focus On Asia